Max S Wicha
Overview
Explore the profile of Max S Wicha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
201
Citations
23134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng F, Zhang S, Chang A, Moon J, Wicha M, Wang S, et al.
Int J Biol Sci
. 2025 Feb;
21(4):1819-1836.
PMID: 39990669
Cancer stem cell (CSC)-targeted immunotherapy has emerged as a novel strategy in cancer treatment in the past decade. However, its efficacy is significantly limited due to the existence of host...
2.
Yuan Y, Tang Y, Fang Z, Wen J, Wicha M, Luo M
Cells
. 2025 Feb;
14(3).
PMID: 39937018
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with transcripts longer than 200 bp, which were initially thought to be noise from genomic transcription without biological function....
3.
Gurrea-Rubio M, Lin F, Wicha M, Mao-Draayer Y, Fox D
Front Immunol
. 2025 Jan;
15:1528478.
PMID: 39840036
Cluster of Differentiation 6 (CD6), an established marker of T cells, has multiple and complex functions in regulation of T cell activation and proliferation, and in adhesion of T cells...
4.
Elaimy A, El-Derany M, James J, Wang Z, Pearson A, Holcomb E, et al.
JCI Insight
. 2024 Sep;
9(21).
PMID: 39287988
End-stage liver disease is marked by portal hypertension, systemic elevations in ammonia, and development of hepatocellular carcinoma (HCC). While these clinical consequences of cirrhosis are well described, it remains poorly...
5.
Luo M, Shen N, Shang L, Fang Z, Xin Y, Ma Y, et al.
Cancer Res
. 2024 Sep;
84(24):4264-4282.
PMID: 39264695
Triple-negative breast cancer (TNBC) contains the highest proportion of cancer stem-like cells (CSC), which display intrinsic resistance to currently available cancer therapies. This therapeutic resistance is partially mediated by an...
6.
Bushnell G, Sharma D, Wilmot H, Zheng M, Fashina T, Hutchens C, et al.
Cancer Res
. 2024 Aug;
84(20):3337-3353.
PMID: 39106452
Patients with breast cancer with estrogen receptor-positive tumors face a constant risk of disease recurrence for the remainder of their lives. Dormant tumor cells residing in tissues such as the...
7.
Sharma D, Hager C, Shang L, Tran L, Zhu Y, Ma A, et al.
Breast Cancer Res
. 2023 Nov;
25(1):144.
PMID: 37968653
Background: Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to relapse and progression. Super-enhancers are regulators of stemness, and BET proteins, which are...
8.
Bushnell G, Sharma D, Wilmot H, Zheng M, Fashina T, Hutchens C, et al.
bioRxiv
. 2023 Oct;
PMID: 37873211
Breast cancer patients with estrogen receptor positive tumors face a constant risk of disease recurrence for the remainder of their lives. Dormant tumor cells residing in tissues such as the...
9.
Orbach S, Brooks M, Zhang Y, Campit S, Bushnell G, Decker J, et al.
Clin Exp Metastasis
. 2023 Jun;
40(4):373.
PMID: 37310520
No abstract available.
10.
Palma A, Bushnell G, Wicha M, Gogna R
Adv Cancer Res
. 2023 Jun;
159:343-372.
PMID: 37268400
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer in the United States. Additionally, the low survival rate makes PDAC the third-leading cause of cancer-related mortality in...